The ubiquitin–proteasome system and its potential application in hepatocellular carcinoma therapy
Authors:
- 1 September 2016
- journal article
- review article
- Published by Elsevier in Cancer Letters
- Vol. 379 (2) , 245-252
Abstract
No abstract availableKeywords
Funding Information
- Foundation of Shanghai Institute of Liver Diseases (10410709400)
- Shanghai Science and Technology Commission (10411950100)
- National Natural Science Foundation of China (81000968, 81101540, 81101637, 81172273, 81272388, 81301820, 81472673)
- Doctoral Fund of Ministry of Education of China (20120071110058)
- National Clinical Key Special Subject of China
This publication has 110 references indexed in Scilit:
- Murine double minute 2 regulates Hu antigen R stability in human liver and colon cancer through NEDDylationHepatology, 2011
- The oncoprotein p28GANK establishes a positive feedback loop in β-catenin signalingCell Research, 2011
- Global dissociation of HuR–mRNA complexes promotes cell survival after ionizing radiationThe EMBO Journal, 2011
- The role of deubiquitinating enzymes in chromatin regulationFEBS Letters, 2010
- REDD1, an inhibitor of mTOR signalling, is regulated by the CUL4A–DDB1 ubiquitin ligaseEMBO Reports, 2009
- The HECT Family of E3 Ubiquitin Ligases: Multiple Players in Cancer DevelopmentCancer Cell, 2008
- Fat10 is an epigenetic marker for liver preneoplasia in a drug-primed mouse model of tumorigenesisExperimental and Molecular Pathology, 2008
- Dual E1 activation systems for ubiquitin differentially regulate E2 enzyme chargingNature, 2007
- Structure-Based Design of Spiro-oxindoles as Potent, Specific Small-Molecule Inhibitors of the MDM2−p53 InteractionJournal of Medicinal Chemistry, 2006
- Small molecule RITA binds to p53, blocks p53–HDM-2 interaction and activates p53 function in tumorsNature Medicine, 2004